公开(公告)号：US20050013854A1

公开(公告)日：2005-01-20

申请号：US10822230

申请日：2004-04-09

Applicant: Raphael Mannino ,  Susan Gould-Fogerite ,  Sara Krause-Elsmore ,  David Delmarre ,  Ruying Lu

Inventor： Raphael Mannino ,  Susan Gould-Fogerite ,  Sara Krause-Elsmore ,  David Delmarre ,  Ruying Lu

IPC: A61K9/127 ,  A61K31/00 ,  A61K31/7048 ,  A61K31/70 ,  C12N15/88

CPC classification number: A61K9/1277 ,  A61K9/1274 ,  A61K31/00 ,  A61K31/135 ,  A61K31/167 ,  A61K31/395 ,  A61K31/60 ,  A61K31/7036 ,  A61K31/7048 ,  A61K38/12 ,  A61K38/14 ,  G01N33/5091

Abstract: Disclosed are novel methods for making cochleates and cochleate compositions that include introducing a cargo moiety to a liposome in the presence of a solvent. Also disclosed are cochleates and cochleate compositions that include an aggregation inhibitor, and optionally, a cargo moiety. Additionally, anhydrous cochleates that include a protonized cargo moiety, a divalent metal cation and a negatively charge lipid are disclosed. Methods of using the cochleate compositions of the invention, including methods of administration, are also disclosed.

Abstract translation: 公开了用于制备耳蜗和耳蜗组合物的新方法，其包括在溶剂存在下将货物部分引入脂质体。 还公开了包括聚集抑制剂和任选的货物部分的耳蜗和耳蜗组合物。 另外，公开了包括质子化货物部分，二价金属阳离子和负电荷脂质的无水耳蜗。 还公开了使用本发明的耳蜗组合物的方法，包括施用方法。

公开(公告)号：US06340591B1

公开(公告)日：2002-01-22

申请号：US09210578

申请日：1998-12-14

Applicant: David Margolis ,  Susan Gould-Fogerite ,  Raphael James Mannino

Inventor： David Margolis ,  Susan Gould-Fogerite ,  Raphael James Mannino

IPC: C12N1563

CPC classification number: C12N15/86 ,  A61K9/127 ,  A61K9/1274 ,  A61K48/00 ,  A61K48/0025 ,  C07K14/005 ,  C12N15/88 ,  C12N15/907 ,  C12N2750/14122 ,  C12N2750/14143

Abstract: An integrative DNA vector and one or more viral proteins having affinity for DNA are packaged in cochleate precipitates. The integrative DNA vector contains one or more therapeutic nucleotide sequences that are preferably positioned between DNA substrates for the proteins. Upon contact with a lipid bilayer of a target cell, the cochleate vector structure delivers one or more of the therapeutic nucleotide sequences and one or more proteins to the interior of the target cell. Upon entry into the cell, the proteins facilitate the integration of the therapeutic nucleotide sequence into the genome of the host cell.

公开(公告)号：US6165502A

公开(公告)日：2000-12-26

申请号：US188120

申请日：1998-11-09

Applicant: James M. Oleske ,  Thomas N. Denny ,  Anthony J. Scolpino ,  Eleonora Feketeova ,  Susan Gould-Fogerite ,  Raphael J. Mannino

Inventor： James M. Oleske ,  Thomas N. Denny ,  Anthony J. Scolpino ,  Eleonora Feketeova ,  Susan Gould-Fogerite ,  Raphael J. Mannino

IPC: A61K9/00 ,  A61K9/127 ,  A61K38/00 ,  A61K39/00 ,  A61K39/002 ,  A61K39/21 ,  A61P31/18 ,  A61P33/00 ,  A61P37/02

CPC classification number: A61K9/1271 ,  A61K2039/55555 ,  Y02A50/41 ,  Y02A50/412 ,  Y02A50/423 ,  Y10S424/812 ,  Y10S436/829

Abstract: A protein-lipid vesicle that can be used to make an autogenous vaccine comprises patient-specific antigen, adjuvant or immunomodulator, and lipid carrier. In addition, a negatively charged lipid component is desirably included. The autogenous vaccine is useful to treat individuals with chronic diseases, including chronic infectious diseases and neoplasias. The chronic infectious diseases that can be treated include disease caused by infection with human immunodeficiency viruses.

Abstract translation: 可用于制备自体疫苗的蛋白质 - 脂质囊泡包括患者特异性抗原，佐剂或免疫调节剂和脂质载体。 此外，期望包括带负电的脂质成分。 自体疫苗可用于治疗慢性疾病的个体，包括慢性传染病和肿瘤。 可治疗的慢性感染性疾病包括由人体免疫缺陷病毒感染引起的疾病。